72.11.Z - Scientific research and development activities
21.20.Z - Manufacture of pharmaceutical preparations and other pharmaceutical products
62.01.Z - Activities related to programming, IT consulting, and related activities
62.02.Z - Activities related to programming, IT consulting, and related activities
70.22.Z - Head office activities and management consultancy
71.12.Z - Engineering activities and related technical consultancy
71.20.B - Inspection and issuing opinions on the technical condition of chimneys and ventilation ducts
72.19.Z - Scientific research and development activities
74.90.Z - Other professional, scientific and technical activities, not elsewhere classified
86.10.Z - Hospital activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -0,2 | -0,4 | -3,2 | -641,5 |
EBITDA | -0,2 | -0,4 | -2,4 | -549,7 |
Short time liabilities | 0,7 | 0,1 | 0,4 | 382,7 |
Equity capital | 2,5 | 6,3 | 17 | 169,5 |
Operating profit (EBIT) | -0,2 | -0,4 | -2,9 | -684,2 |
Assets | 5,9 | 10,9 | 21,9 | 100,8 |
Net profit (loss) | -0,2 | -0,4 | -3,2 | -641,5 |
Cash | 0 | 1,1 | 9,3 | 765,9 |
Liabilities and provisions for liabilities | 3,4 | 4,6 | 4,9 | 6,9 |
Net income from sale | 0 | 0 | 0 | 0 |
Working assets | 0,2 | 1,8 | 11,3 | 526 |
Depreciation | 0 | 0 | 0,5 | -∞ |
% | % | % | p.p. | |
Profitability of capital | -9,8 | -6,8 | -18,7 | -11,9 |
Equity capital to total assets | 41,8 | 57,7 | 77,5 | 19,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 2 147 483 648 | 2 147 483 648 | 2 147 483 648 | 0 |
Current financial liquidity indicator | 0.07114310562610626 | 0.39170533418655396 | 2.2929739952087402 | 1,9 |
Net dept to EBITDA | 0.1829490065574646 | 2.932152271270752 | 3.9076199531555176 | 1 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane